Safety and efficacy of adalimumab for the treatment of severe alopecia areata: case series of three patients

J Cutan Med Surg. Jul-Aug 2012;16(4):257-60. doi: 10.1177/120347541201600407.

Abstract

Background: Current therapeutic options for extensive alopecia areata (AA) often lead to disappointing results.

Objective: To study the efficacy and safety of adalimumab in patients with severe AA.

Methods: This was a prospective, open-label, single-center, pilot study. Three subjects of the planned 10 were enrolled and received two weekly subcutaneous (SC) loading doses of adalimumab 80 mg followed by 40 mg SC every week for 6 months. Patients were evaluated for efficacy and safety on a monthly basis.

Results: Enrolment in this trial was stopped following publication of studies showing no improvement in patients with AA treated with tumor necrosis factor α antagonists. One patient had a favorable response to adalimumab, whereas the two other patients had no benefit from the therapy. Adalimumab was well tolerated by patients with AA.

Conclusion: Adalimumab was well tolerated in patients with AA but did not induce clinically significant hair regrowth.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Adult
  • Alopecia Areata / drug therapy*
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Female
  • Humans
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Pilot Projects
  • Prospective Studies
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal, Humanized
  • Adalimumab